| Symbol
| IGFBP3
| contributors: mct/shn/pgu - updated : 10-03-2014
|
| HGNC name
| insulin-like growth factor binding protein 3
|
| HGNC id
| 5472
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
| |
in acromegalic patients | | tumoral
|
|
| --low
|
| |
in breast cancer | | tumoral
|
|
| --over
|
|
high expression of IGFBP-3 is associated with a low risk of cancer, whereas low expression of IGFBP3 increases the risk of cancer  | |
| Susceptibility
|
prostate cancer with advanced stage to breast cancer |
| Variant & Polymorphism
| C allele may cumulatively increase the risk for prostate cancer metastasis and for having tumors with a biologically more aggressive phenotype |
|
homozygosity for the variant allele in polymorphisms A-202C, G227C, 5606InsA, and C5827T associated with the level of blood IGFBP-3 protein and increasing the risk of breast cancer |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | digestive | oesophagus | |
| may thus be useful target for improved and more individualized treatments for patients with esophageal squamous cell carcinoma | | neurosensorial | visual | retina | |
| use of exogenous IGFBP3 in patients at risk for retinal neovascularization would have protective effects (suppresses retinopathy of prematurity through suppression of oxygen-induced vessel loss and promotion of vascular regrowth) | | cardiovascular | atheroma | | |
| potentially a therapeutic target for treatment of ischemic conditions | | cancer | | | |
| is a new type of cancer therapy that inhibits cancer proliferation by inducing senescence |
| | | |
|
| GFBP3-deficient mice displa a dose-dependent increase in oxygen-induced retinal vessel loss and Igfbp3(-/-) mice had a 31% decrease in retinal vessel regrowth versus controls after returning to room air ( |